Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 | 370 | 364 |
| Expenses | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 | 235 | 264 |
| Operating Profit | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 | 110 | 136 | 100 |
| OPM % | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% | 30% | 37% | 27% |
| Other Income | 6 | 5 | 2 | -18 | 3 | 4 | 3 | 4 | 5 | 4 | 4 | 36 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 6 |
| Profit before tax | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 | 109 | 133 | 129 |
| Tax % | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% | 29% | 29% | 26% |
| Net Profit | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 | 95 | 96 |
| EPS in Rs | 39.50 | 43.42 | 28.05 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | 57.92 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 9m | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,408 | 1,433 |
| Expenses | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | 845 | 616 | 949 | 967 |
| Operating Profit | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 | 307 | 319 | 459 | 466 |
| OPM % | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% | 27% | 34% | 33% | 33% |
| Other Income | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | -5 | 10 | 15 | 49 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 | 27 | 17 | 24 | 24 |
| Profit before tax | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 | 273 | 312 | 450 | 490 |
| Tax % | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% | 26% | 25% | 27% | |
| Net Profit | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | 201 | 234 | 327 | 357 |
| EPS in Rs | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 141.22 | 196.94 | 214.99 |
| Dividend Payout % | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% | 215% | 89% | 104% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 4% | 1% | 8% | 13% | ||
| Compounded Profit Growth | 20% | 5% | 19% | 11% | ||
| Stock Price CAGR | 23% | 1% | 4% | -10% | ||
| Return on Equity | 31% | 35% | 43% | 62% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 575 | 647 | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 | 522 | 520 | 508 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | 12 | 10 | 8 | 9 |
| Other Liabilities | 192 | 215 | 258 | 219 | 250 | 269 | 275 | 269 | 338 | 247 | 250 | 308 |
| Total Liabilities | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 841 |
| Fixed Assets | 132 | 111 | 115 | 104 | 101 | 101 | 104 | 112 | 144 | 128 | 116 | 102 |
| CWIP | 7 | 30 | 9 | 17 | 11 | 21 | 39 | 41 | 32 | 6 | 11 | 14 |
| Investments | 42 | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 603 | 711 | 797 | 1,639 | 954 | 1,053 | 843 | 736 | 925 | 660 | 667 | 726 |
| Total Assets | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 841 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 83 | 107 | 54 | -130 | 235 | 247 | 170 | 236 | 228 | 169 | 338 | |
| Cash from Investing Activity | -68 | -75 | -48 | 1,270 | 165 | -32 | -26 | -22 | -7 | 10 | 1 | |
| Cash from Financing Activity | -12 | -15 | -22 | -30 | -883 | -387 | -289 | -98 | -418 | -235 | -344 | |
| Net Cash Flow | 4 | 17 | -16 | 1,109 | -483 | -172 | -145 | 116 | -197 | -56 | -5 | |
| Free Cash Flow | 38 | 75 | 24 | -157 | 212 | 196 | 132 | 198 | 207 | 168 | 323 | |
| CFO/OP | 136% | 138% | 147% | 117% | 106% | 128% | 87% | 100% | 102% | 78% | 96% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 49 | 39 | 64 | 28 | 30 | 26 | 22 | 27 | 34 | 27 | 57 | 43 |
| Inventory Days | 140 | 145 | 243 | 154 | 139 | 113 | 138 | 124 | 136 | 120 | 152 | 137 |
| Days Payable | 55 | 67 | 128 | 124 | 106 | 105 | 209 | 185 | 239 | 184 | 239 | 192 |
| Cash Conversion Cycle | 134 | 118 | 179 | 58 | 63 | 34 | -49 | -34 | -69 | -37 | -30 | -13 |
| Working Capital Days | 69 | 52 | 94 | 42 | 22 | 23 | 7 | 17 | 15 | 19 | 48 | 30 |
| ROCE % | 15% | 18% | 16% | 78% | 20% | 29% | 29% | 38% | 45% | 45% | 48% | 84% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% |
| FIIs | 7.38% | 7.60% | 6.24% | 6.39% | 6.61% | 7.01% | 6.86% | 6.99% | 7.24% | 6.97% | 6.20% | 6.33% |
| DIIs | 12.30% | 12.66% | 13.72% | 14.56% | 14.84% | 14.71% | 14.21% | 14.15% | 13.90% | 13.84% | 13.67% | 12.44% |
| Public | 28.50% | 27.92% | 28.22% | 27.24% | 26.74% | 26.47% | 27.11% | 27.03% | 27.05% | 27.37% | 28.30% | 29.41% |
| No. of Shareholders | 57,919 | 56,730 | 56,778 | 55,923 | 54,792 | 53,736 | 53,993 | 52,478 | 50,006 | 49,302 | 50,883 | 49,056 |
Fundamentals
Market Cap₹ 9,455 Cr.
Current Price₹ 5,696
Stock P/E28.4
Book Value₹ 316
ROCE83.9 %
ROE61.9 %
Dividend Yield2.72 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)13%
Compounded Profit Growth (TTM)11%
Standalone figures.
Valuation
Market capRs 8,897 Cr
Enterprise valueRs 8,721 Cr
P/E (TTM)24.93x
Price to book16.96x
Price to sales6.21x
EV / EBITDA16.94x
EV / EBIT17.77x
EV / sales6.09x
Price to cash flow26.34x
Earnings yield4.01%
Dividend yield3.82%
P/E, 3-year average34.17x
P/B, 3-year average15.56x
P/E, 5-year average35.33x
P/B, 5-year average13.91x
Profitability
Operating margin (excl. other income)32.57%
Operating margin (incl. other income)33.67%
EBITDA margin35.93%
Pre-tax margin34.21%
Net profit margin24.91%
Net margin, latest quarter26.44%
ROE61.59%
ROCE83.53%
ROA39.98%
ROE, 3-year average45.46%
ROCE, 3-year average60.83%
ROA, 3-year average30.23%
ROE, 5-year average39.82%
ROCE, 5-year average53.24%
ROA, 5-year average26.86%
ROIC (approx.)102.31%
Tax rate27.33%
Other income / net worth2.95%
Growth
Sales growth (latest year)50.72%
Profit growth (latest year)39.46%
Sales CAGR, 3 years4.62%
Sales CAGR, 5 years6.90%
Profit CAGR, 3 years12.52%
Profit CAGR, 5 years13.08%
Sales growth QoQ-1.82%
Profit growth QoQ1.64%
Sales growth YoY (latest quarter)7.37%
Profit growth YoY (latest quarter)45.29%
Per share
EPS (TTM)Rs 215.00
EPS (latest year)Rs 196.94
EPS (latest quarter)Rs 57.92
EPS, 3-year averageRs 153.08
EPS, 5-year averageRs 142.69
Book value per shareRs 316.01
Sales per shareRs 863.25
Cash flow per shareRs 203.50
Free cash flow per shareRs 194.59
Dividend per share (latest year)Rs 205.01
Dividend per share, 3-year averageRs 196.67
Dividend per share, 5-year averageRs 147.51
Dividends
Dividend payout104.10%
Dividend payout, 3-year average135.79%
Dividend payout, 5-year average104.27%
Efficiency
Asset turnover1.67x
Fixed asset turnover13.77x
Inventory turnover3.50x
Inventory days104 days
Debtor days43 days
Debtors turnover8.57x
Creditor days192 days
Cash conversion cycle-13 days
Working capital days30 days
Leverage
Total debtRs 9 Cr
Cash and bankRs 185 Cr
Net debtRs -176 Cr
Debt to equity0.02x
Net debt / EBITDA-0.34x
Interest coverage860.95x
Current ratio (filing 2026-03-31)2.18x
Quick ratio (filing 2026-03-31)1.65x
Trade payables (filing 2026-03-31)Rs 192 Cr
Owners' fund to total sources62.35%
Debt to assets1.10%
Cash flow
Cash from Operating Activity (latest year)Rs 338 Cr
Cash from Investing Activity (latest year)Rs 1 Cr
Cash from Financing Activity (latest year)Rs -344 Cr
Net Cash Flow (latest year)Rs -5 Cr
Free cash flow (latest year)Rs 323 Cr
FCFE (approx.: FCF + change in debt)Rs 325 Cr
Cash from ops / profit, 5 years1.08x
Sales to cash flow4.17x
Statement figures
Net sales (TTM)Rs 1,433 Cr
Net sales (latest year)Rs 1,408 Cr
Sales (latest quarter)Rs 364 Cr
Operating profit excl. other income (latest year)Rs 459 Cr
Operating profit (latest quarter)Rs 100 Cr
Other income (TTM)Rs 49 Cr
EBITDA (TTM)Rs 515 Cr
PBDT (TTM)Rs 514 Cr
Profit before tax (TTM)Rs 490 Cr
Tax (latest year)Rs 123 Cr
Net profit (TTM)Rs 357 Cr
Net profit (latest year)Rs 327 Cr
Net profit (latest quarter)Rs 96 Cr
Depreciation (TTM)Rs 24 Cr
Depreciation (latest quarter)Rs 6 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 479 Cr
Total expenditure (latest year)Rs 949 Cr
Total income (latest year)Rs 1,423 Cr
Share capitalRs 17 Cr
ReservesRs 508 Cr
Shareholders' fundsRs 525 Cr
Total assetsRs 841 Cr
Net blockRs 102 Cr
Capital work in progressRs 14 Cr
ReceivablesRs 164 Cr
InventoryRs 137 Cr
Other liabilitiesRs 308 Cr
Shares outstanding (crore)1.66
Ownership
Promoter holding51.82% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 24.9 is at the 12th percentile of its own 8.7-year range
(median 37.5, low 7.3, high 62.1).
P/B 16.96 is at the 87th percentile (median 11.16).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | PGHL | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -1.0% | -2.8% | +1.7 pts |
| 1 month | -7.2% | -6.8% | -0.4 pts |
| 3 months | -15.6% | -7.6% | -8.0 pts |
| 6 months | +11.7% | +0.4% | +11.3 pts |
| 1 year | -15.8% | -9.9% | -5.9 pts |
| 2 years | +2.6% | -13.6% | +16.1 pts |
| 3 years | +4.8% | +14.2% | -9.3 pts |
| 5 years | -2.9% | +27.9% | -30.8 pts |
25 mutual fund schemes hold about ₹832 Cr.
Over three months 15 bought more and 4 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Nippon India Small Cap Fund | 0.48% | 401 | +3% |
| UTI MNC Fund | 3.92% | 110 | -7% |
| DSP Healthcare Fund | 2.40% | 92 | -1% |
| Aditya Birla SL MNC Fund | 1.66% | 55 | +6% |
| Tata India Pharma & Healthcare Fund | 2.51% | 39 | +66% |
| UTI Healthcare Fund | 2.00% | 29 | -2% |
| Aditya Birla SL Consumption Fund | 0.42% | 26 | +6% |
| Aditya Birla SL Pharma & Healthcare Fund | 1.84% | 20 | -1% |
| Bajaj Finserv Small Cap Fund | 0.62% | 16 | +100% |
| Aditya Birla SL Business Cycle Fund | 0.89% | 16 | +2% |
| WOC Pharma and Healthcare Fund | 1.25% | 11 | +13% |
| Tata India Consumer Fund | 0.28% | 8 | +100% |
| Baroda BNP Paribas Health and Wellness Fund | 0.57% | 3 | +18% |
| Sundaram LT Micro Cap Tax Adv Fund-Sr III- | 2.70% | 2 | +8% |
| Sundaram LT Micro Cap Tax Adv Fund-Sr VI- | 2.86% | 1 | +8% |
| Sundaram LT Tax Adv Fund-Sr III | 2.88% | 1 | +8% |
| Sundaram LT Micro Cap Tax Adv Fund-Sr IV | 2.65% | 1 | +8% |
| Sundaram LT Micro Cap Tax Adv Fund-Sr V- | 2.84% | 1 | +7% |
| Sundaram LT Tax Adv Fund-Sr IV | 3.15% | 1 | +10% |
| WOC Dividend Yield Fund | 0.25% | 0 | +100% |
| Bandhan BSE Healthcare Index Fund | 0.28% | 0 | +4% |
| Motilal Oswal BSE 1000 Index Fund | 0.02% | 0 | +9% |
| UTI Balanced Advantage Fund | 0.00% | 0 | -100% |
| ICICI Pru Small Cap Fund | 0.00% | 0 | -100% |
| ICICI Pru Small Cap Fund | 0.00% | 0 | -100% |
Red flags
F-score 6 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹364 Cr +7.4% vs Jun 2025.
Net profit ₹96 Cr +45.5%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-08-27 | Dividend - Rs 45 Per Share | |
| 2026-02-12 | Interim Dividend - Rs 110 Per Share & Special Dividend Rs 50 Per Share | |
| 2025-08-22 | Dividend - Rs 45 Per Share | |
| 2025-02-21 | Interim Dividend - Rs 80 Per Share | |
| 2024-11-28 | Annual General Meeting/Dividend - Rs 60 Per Share | |
| 2024-02-14 | Interim Dividend - Rs 50 Per Share & Special Dividend Rs 150 Per Share | |
| 2023-11-23 | Annual General Meeting/Dividend - Rs 50 Per Share | |
| 2023-02-13 | Interim Dividend - Rs 45 Per Share | |
| 2022-11-15 | Annual General Meeting/Dividend - Rs 11.50 Per Share | |
| 2022-05-12 | Interim Dividend - Rs 41 Per Share | |
| 2021-11-02 | Annual General Meeting/Dividend - Rs 40 Per Share/Special Dividend - Rs 90 Per Share | |
| 2020-11-18 | Annual General Meeting/Dividend - Rs 42 Per Share Special Dividend - Rs 188 Per Share | |
| 2019-05-23 | Annual General Meeting / Special Dividend - Rs 416 Per Share/ Final Dividend - Rs 24 Per Share | |
| 2018-05-21 | Annual General Meeting/ Dividend - Rs 15 Per Share | |
| 2017-05-25 | Annual General Meeting/Dividend-Rs 11/- Per Share (Revised) | |
| 2016-04-22 | Annual General Meeting/Dividend - Rs 7.50/- Per Share (Book Closure Dates Revised) | |
| 2015-03-30 | Annual General Meeting / Dividend - Rs 6/- Per Share | |
| 2014-03-10 | Annual General Meeting/Dividend - Rs 8.50/- Per Share | |
| 2013-03-07 | Annual General Meeting/Dividend Rs 2.50 Per Share | |
| 2012-03-27 | Annual General Meeting | |
| 2011-03-21 | Annual General Meeting | |
| 2010-10-22 | Interim Dividend-Rs.95/- Per Share (Purpose Revised) | |
| 2010-03-18 | Dividend-Rs.20/- Pr Share | |
| 2009-04-06 | Agm/Div-Rs.17.50 Per Shre | |
| 2008-04-04 | Agm/Div-Rs10 Per Share | |
| 2007-03-21 | Agm/Div-Fin Rs20+Int Rs10purpose Revised | |
| 2006-04-12 | Agm/Div-Rs.15/- Per Sh |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd (PGHL) has a market capitalisation of Rs 9,455 Cr. at the 2026-10-01 close.
What is the P/E ratio of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd trades at a P/E of 28.4 on trailing twelve-month profit, at the 2026-10-01 close.
What were Procter & Gamble Health Ltd's latest quarterly results?
In the Jun 2026 quarter, Procter & Gamble Health Ltd sales was Rs 364 Cr (+7.4% vs Jun 2025) and net profit was Rs 96 Cr.
What is the 52-week high and low of Procter & Gamble Health Ltd?
The 52-week high is Rs 6,975.00 and the 52-week low is Rs 4,707.00.